^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan-cancer

Published date:
07/23/2022
Excerpt:
Arylsulfatase I was highly expressed in 15 cancer types, with significant expressions in HNSC….Elevated ARSI expressions conferred poor tolerance to daporinad and sinularin, but increased cell sensitivity to dasatinib and XAV939.
DOI:
10.1002/jcla.24600